Endeavor

Immunotherapy May Help Prevent Acute Myeloid Leukemia Relapse After Transplant

Early phase 1 trial results indicate safety and efficacy of donor gamma delta T cell infusions

Overcoming Rare Synovial Sarcoma with a Revolutionary New Treatment

After years of treatments, a first-of-its-kind cell therapy is offering new possibilities for one synovial sarcoma patient

New CAR T-Cell Therapy Shows Promising Results for Advanced Multiple Myeloma

Early trial results show high success rates and manageable side effects

Moffitt Study Explores Key Risk Factors To Better Personalize CAR T-Cell Therapy

The study analyzed ide-cel to help physicians intervene and reduce toxicities in multiple myeloma patients

Moffitt Patient Is First To Receive Second CAR T Therapy for Ovarian Cancer

Patient receives second dose of CAR-T immunotherapy for ovarian cancer with special approval from the FDA.

Newly Approved CAR T-Cell Therapy Gives Acute Lymphoblastic Leukemia a New Personalized Option

Novel design and tumor-guided dosing may reduce side effects while maintaining encouraging efficacy

Newly Approved Cell Therapy Afami-Cel Shows Long-Term Tumor Control in Synovial Sarcoma

Phase 2 clinical trial data suggests the engineered T cells can stay active in the body for more than three years

New Immunotherapy Combination Shows Promise in Advanced Lung Cancer

Adding pembrolizumab to TIL therapy shrunk tumors in almost half of trial patients

Moffitt Experts Share Discoveries Driving Innovation in Cancer Immunotherapy

The Society for Immunotherapy of Cancer brings together industry leaders to highlight new research and clinical applications in immunotherapy